Telotristat With Lutathera in Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2034-06-30
Target enrollment:
Participant gender:
Summary
This trial will test the hypothesis that Telotristat treatment increases the antitumor
efficacy of Lutetium Lu 177 Dotatate therapy in neuroendocrine tumors (NETs).